KRAS and pancreatic adenocarcinoma: Quite contradictorily, a retrospective analysis of PAAD patients revealed that patients that have both KRASG12D mutation and TP53 mutation conferred better OS than other point mutations of KRAS (G12V/R/others), along with the TP53 mutation [130].